KUALA LUMPUR, November 21 – The total Malaysian elderly population is estimated at 2.4 million or 7.5% of the total Malaysian population. According to the Department of Statistics Malaysia (DOSM), ages 60 and above are increasing yearly and Malaysia is set to become a nation of the elderly by 2030, with citizens over 60 reaching 15.3% of the total population. This means 1 out of every 6 people will be over 60 years of age in 8 years’ time. 

This spells significant threats to Malaysia’s health care industry and society in general, and escalates common, degenerative and chronic diseases and immune deficiencies – leading to disability, immobility and dependency and premature deaths amongst Malaysians. In addition, Alzheimer’s disease will increase about 50 million people worldwide are Alzheimer’s patients. The future treatment for degenerative diseases will not be drugs nor surgeries, but cell therapy.

University Kebangsaan Malaysia (UKM) which conducts research into regenerative medicine therapy (RMT) shared that stem cells therapies are a viable avenue to restore organ functions via regeneration and functional repair of damaged tissues. There are two types of human stem cells Hematopoietic Stem Cells (HSCs), found in cord blood, bone marrow & peripheral blood and Mesenchymal Stem Cells (MSCs), found in Wharton’s Jelly of the umbilical cord, bone marrow, fat tissue and tooth pulp.

It is the MSCs that are multipotent as they carry and release a wide range of growth factors for repair and rejuvenation of various organ parts. Enters AlphaCelle – the world’s first integrated stem cell therapy combining stems cells, high electric potential and exosomes. AlphaCelle sources stem cells ethically from umbilical cords of young and healthy women post-delivery from hospitals, ensuring the highest quality and energy mesenchymal stem cells (MSCs) available. 

The stem cells are then processed with the most advanced biotechnology under stringent hygienic condition, governed by Current Good Manufacturing Practices (cGMP) compliant by the Malaysian Ministry of Health and the National Pharmaceutical Regulatory Agency (NPRA). Most crucially, the live mesenchymal stem cells have a maximum of 8 hours’ time-window from the process of de-thawing from cryo-frozen form to the delivery of it intravenously that ensure maintaining the continuous living nature and quality of the MSCs.

AlphaCelle’s brand promise is “Life Anew”, suggesting with regenerative medicine, everyone’s lives can be restarted, youthful and away from pain. Its mission is to capitalize stem cell therapy for every Malaysian. In short, AlphaCelleaims to help delay aging, reduce diseases so Malaysians can live fulfilling live into their golden years with dignity. AlphaCelle recently conducted rolled out public education workshops with their panel of medical practitioners to discuss the future of regenerative therapies. 

Pocket News